Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New digital tool aims to boost fertility awareness in cancer patients

NCT ID NCT07642531

Knowledge-focused Sponsor: Biruni University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will develop and test a free, cloud-based platform to educate women aged 18-45 with early-stage gynecologic cancer about fertility preservation options. Researchers will compare awareness, knowledge, and attitudes between a group using the platform and a group receiving standard brochures. The goal is to see if the digital tool helps women make more informed decisions about their fertility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modular cloud-based educational platform
What this could lead to
If effective, this platform could become a free, scalable tool to help women with gynecologic cancer make informed decisions about fertility preservation.
What could go wrong
This is an early-stage trial testing awareness, not a treatment. The platform may not change actual behavior or outcomes, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women of reproductive age between the ages of 18 and 45, * Diagnosed with early stage cervical cancer, ovarian cancer, tubal cancer and endometrial cancer and whose treatment has not started, * Those who have a smartphone and can use the platform, * Volunteering and giving informed consent, * Turkish literate, * Individuals who do not report mental problems * Do not have children, * Marital status is married or single. Exclusion Criteria: * Neurological disease (e.g., stroke, multiple sclerosis) or cognitive impairment, * Advanced-stage gynecologic cancers, * Failure to complete the follow-up period, * Initiation of oncologic treatment during the study period, * Non-completion or incomplete completion of the data collection instruments, * Non-use of the platform among participants allocated to the intervention group, * History of prior cancer treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early stage endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical carcinoma endometrial cancer fallopian tube cancer female reproductive organ cancer ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fertility preservation Gynecologic cancers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Biruni University

    Istanbul, Zeytinburnu, 34020, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.